Key result
Fibroblast-specific deletion of the CNP receptor GC-B in mice exacerbated cardiac fibrosis, hypertrophy, and contractile dysfunction in response to angiotensin II infusion or transverse aortic constriction, with more pronounced effects in females.
Why the study?
The local mediators that counterregulate excessive activation of cardiac fibroblasts in response to injury remain unclear, and the role of endogenous C-type natriuretic peptide is not fully known.
Endogenous C-type natriuretic peptide signaling via GC-B in cardiac fibroblasts exerts critical antifibrotic and antihypertrophic effects, particularly in females, suggesting a potential therapeutic target for pathological cardiac remodeling.
Answers are grounded in this paper and cite their sources.
Endogenous CNP/GC-B signaling in fibroblasts merits targeted study; leaves open whether pathway agonism attenuates human cardiac fibrosis.
Excessive activation of cardiac fibroblasts (CFs) in response to injury provokes cardiac fibrosis, stiffness, and failure. The local mediators counterregulating this response remain unclear. Exogenous C-type natriuretic peptide (CNP) exerts antifibrotic effects in preclinical models. To unravel the role of the endogenous hormone, we generated mice with fibroblast-restricted deletion (KO) of guanylyl cyclase-B (GC-B), the cGMP-synthesizing CNP receptor. CNP activated GC-B/cGMP signaling in human and murine CFs, preventing proliferative and promigratory effects of angiotensin II (Ang II) and TGF-β. Fibroblast-specific GC-B-KO mice showed enhanced fibrosis in response to Ang II infusions. Moreover, after 2 weeks of mild pressure overload induced by transverse aortic constriction (TAC), such KO mice had augmented cardiac fibrosis and hypertrophy, together with systolic and diastolic contractile dysfunction. This was associated with increased expression of the profibrotic genes encoding collagen I, III, and periostin. Notably, such responses to Ang II and TAC were greater in female as compared with male KO mice. Enhanced Ang II-induced CNP expression in female hearts and augmented GC-B expression and activity in female CFs may contribute to this sex disparity. The results show that paracrine CNP signaling in CFs has antifibrotic and antihypertrophic effects. The CNP/GC-B/cGMP pathway might be a target for therapies combating pathological cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Werner et al. (2023) studied Cardiac fibrosis and adverse cardiac remodeling. Fibroblast-specific deletion of GC-B (Npr2) vs. Control littermates (Npr2fl/fl without Cre) was evaluated on Cardiac fibrosis and hypertrophy. Fibroblast-specific deletion of the CNP receptor GC-B in mice exacerbated cardiac fibrosis, hypertrophy, and contractile dysfunction in response to angiotensin II infusion or transverse aortic constriction, with more pronounced effects in females.
Synapse has enriched 10 related papers. Consider them for comparative context: